Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ORY-1001 (Iadademstat) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Evidence of clinical efficacy continues to be robust and consistent with previously reported data for ORY-1001 (Iadademstat), with an objective response rate (ORR) of 81% (22 of 27 evaluable patients); of these, 64% were complete remissions and 36% parti...
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iadademstat (ORY-1001), is an oral, highly potent and selective inhibitor of the epigenetic enzyme LSD1, a chromatin remodeler that interacts with a variety of transcription factors involved in SCLC, other solid tumors and hematological cancers such as a...
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzon’s clinical stage LSD1 inhibitor, iadademstat, in different types of solid and hematological cancers.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : Iadademstat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : European Commission
Deal Size : $2.0 million
Deal Type : Funding
Details : The funding is for Oryzon’s project, Iadademstat (ORY-1001) a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : European Commission
Deal Size : $2.0 million
Deal Type : Funding
Lead Product(s) : BO-112,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and therefore visible to the immune system.
Product Name : BO-112
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : BO-112,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination of iadademstat with azacitidine continues to show a good safety profile, with only two serious adverse events reported as probably related to treatment.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers. Robust signals of clinical efficacy, with ORR of 83%, of which 67...
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 06, 2021
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Iadademstat is an investigational, oral, small molecule covalent inhibitor of the epigenetic enzyme LSD1, a chromatin remodeler that interacts with a variety of transcription factors involved in leukemia and other cancers.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 02, 2021
Lead Product(s) : Iadademstat,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BO-112,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Highlight Therapeutics To Present Phase 2 Data at AACR
Details : Presentation will cover Phase IIa open-label clinical study of intratumoral administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer.
Product Name : BO-112
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : BO-112,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable